February 3, 2026 02:34 PM ESTUpdated 04:31 PM

'Turning around the Titanic': How the incoming PBM reforms will transform CMS

Zachary Brennan

Senior Editor

The Centers for Medicare and Medicaid Services has never played a significant role in regulating pharmacy benefit managers, the middlemen that have historically relied on …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

'Turning around the Titanic': How the incoming PBM reforms will transform CMS

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Novo cites MFN as disappointing 2026 sales forecast triggers selloff

Updated: Do Pfizer’s monthly GLP-1 data justify Metsera’s $10B price tag?

One cancer drug steps back, and obesity asset steps forward, as Pfizer reports earnings

Ultragenyx unwraps data that may be central to its gene therapy resubmission

AstraZeneca gets CRL for self-injectable pen version of lupus drug Saphnelo

Biggest SCOPE Buzz: Two Disruptors in Clinical Research Are Redefining Enrollment Speed

'Turn­ing around the Ti­tan­ic': How the in­com­ing PBM re­forms will trans­form CMS

Zachary Brennan

Senior Editor

Sign up to read this article for free.

No­vo cites MFN as dis­ap­point­ing 2026 sales fore­cast trig­gers sell­off

Up­dat­ed: Do Pfiz­er’s month­ly GLP-1 da­ta jus­ti­fy Met­sera’s $10B price tag?

One can­cer drug steps back, and obe­si­ty as­set steps for­ward, as Pfiz­er re­ports earn­ings

Ul­tragenyx un­wraps da­ta that may be cen­tral to its gene ther­a­py re­sub­mis­sion

As­traZeneca gets CRL for self-in­jectable pen ver­sion of lu­pus drug Saph­ne­lo

Biggest SCOPE Buzz: Two Dis­rup­tors in Clin­i­cal Re­search Are Re­defin­ing En­roll­ment Speed

'Turning around the Titanic': How the incoming PBM reforms will transform CMS

Novo cites MFN as disappointing 2026 sales forecast triggers selloff

Updated: Do Pfizer’s monthly GLP-1 data justify Metsera’s $10B price tag?

One cancer drug steps back, and obesity asset steps forward, as Pfizer reports earnings

Ultragenyx unwraps data that may be central to its gene therapy resubmission

AstraZeneca gets CRL for self-injectable pen version of lupus drug Saphnelo

Biggest SCOPE Buzz: Two Disruptors in Clinical Research Are Redefining Enrollment Speed